In the News

1859 News Items found
A new discovery made by Memorial Sloan Kettering researchers and published in the journal <i>Nature Genetics</i>, identifies a mechanism for the triggering of solid tumors — including most types of cancers that affect children and young adults. For more information or to arrange interviews, e-mail Rebecca Williams at [email protected].
Mount Rushmore viewed through face-detection software.
Taking a cue from smartphone technology, scientists are using face-recognition algorithms to improve RNA interference.
A cell in the process of dividing
In the Lab
MSK researchers are learning how cells are able to recognize and correct errors that occur during cell division.
An illustration of CRISPR-Cas9
In the Lab
A freely accessible software program provides researchers with an easy way to optimize a popular genome-editing tool.
Doctor in green surgical scrubs wearing glasses and cap looking at camera.
Q&A
Learn how MSK specialists treat head and neck cancers using the most innovative approaches.
Image of liver with tumors
In the Clinic
A retrospective study from MSK has found that colorectal cancer patients with liver metastases live an average of two years longer when they receive an additional treatment called hepatic arterial infusion (HAI).
James Eastham, Chief of the Urology Service at Memorial Sloan Kettering
In the Clinic
MSK surgeon James Eastham explains the pros and cons of PSA testing and weighs in on a new US Preventive Services Task Force guideline.
photo of blood vials
Finding
Why do some patients respond to immunotherapy while others do not? Blood may hold the answer.
Researchers from Memorial Sloan Kettering Cancer Center (MSK) and their colleagues at the University of Pennsylvania (UPenn), in collaboration with the Parker Institute for Cancer Immunotherapy (PICI), studied changes in the blood of patients with stage IV melanoma who were all treated with the PD-1 drug pembrolizumab. Researchers looked at circulating immune cells called T cells that showed signs of being “reinvigorated” by the PD-1 therapy. For more information or to arrange interviews please e-mail Rebecca Williams at [email protected].
Physician standing in front of a whiteboard
Finding
Learn more about entrectinib, a targeted therapy being evaluated in patients with solid tumors.